

Pharmacy & Therapeutics Committee

Meeting Minutes

Thursday, November 21th, 2024

7:00 a.m. to 8:45 a.m.

Video Call: <https://meet.google.com/tni-wias-qke>

Committee Members Present:

Cole Sloan, PharmD, BCPS, BCGP,
Committee Chair

Bryan Larson, PharmD, P&T Manager

Susan Siegfroid, MD

Clayton Grace, RPh

Rocky Parker, PharmD, MBA

Committee Members Excused: None

Dept. of Health/Div. of Health Care Financing Staff Present:

Sepideh Daeery, PharmD

Ngan Huynh, PharmD

Luis Moreno, PharmD, CDCES

Kyu Yun Park, PharmD

Stephanie Byrne, PharmD

Craig Hummel, MD

Yoon Kim-Butterfield, MD

Andrea Rico, CPhT

University of Utah Drug Regimen Review Center Staff Presenter:

Monet Luloh, PharmD

Other Individuals Present:

Adam Gold, NS Pharma

Alyson Evans, ITF Therapeutics

Amy Hale, J&J

Becca Manola

Cheryl Donahue, Sarepta

Jason Smith, Gilead

Lauren Heath, DRRC

Lori Amels, Sarepta

Nathaniel Elia, Sarepta

Robin Wells, NS Pharma

Russell Butterfield, University of Utah
Neurology

Stephanie Kennedy, Sarepta

Lisa Bucciarelli, NS Pharma

A Aikins

Emily Cooper

Artia Solutions

Valerie Gonzales, DRRC

Joe Sullivan

Joan Schindler, Sarepta

Pharmacy & Therapeutics Committee

Meeting Minutes

Meeting conducted by: Committee Chair

1. **Welcome & Housekeeping:** Committee Chair opened the meeting and reminded everyone to sign the rosters.
2. **Review and Approval of September Minutes:** Clayton Grace made a motion to approve the minutes from the September meeting. Cole Sloan seconded the motion. All in favor, motion passed.
3. **Drug Utilization Review (DUR) Board update:** The DUR Board met last week to discuss several Rare Disease prior authorizations. The DUR Board will meet in December to discuss CAR-T therapies.
4. **Topic: Duchenne Muscular Dystrophy**
 - a. Presented by Monet Luloh, DRRC
 - b. Public Comment:
 1. Russell Butterfield, MD from University of Utah Neurology
 2. Adam Gold from NS Pharma
 3. Becca Manola
 4. Stephanie Kennedy from Sarepta
 - c. Committee Discussion:
 1. Bryan Larson asked if in the head-to-head trial, deflazacort and prednisone showed similar efficacy. Monet Luloh confirmed that is correct.
 2. Cole Sloan asked regarding the differences in weight-gain side effects of deflazacort vs. prednisone. Monet Luloh responded that the trial needed to be reviewed.
 3. Bryan Larson asked if there is a head-to-head trial between vamorolone, prednisone, or deflazacort. Monet Luloh responded that there is not one between vamorolone and deflazacort, and there might be one trial between vamorolone and prednisone that focused on safety and not efficacy between drugs. Russell Butterfield commented that the trial shows the efficacy is the same with vamorolone and prednisone in terms of decline in motor function
 4. Cole Sloan made a motion to include at least one-FDA

Pharmacy & Therapeutics Committee

Meeting Minutes

approved corticosteroid for DMD that is recommended by guidelines and experts to start early and continue after loss of ambulation. Bryan Larson made note to include the prednisone even though it's not FDA-approved for DMD but has been a standard of care for a long time as a general of start therapy. Russell Butterfield confirmed that prednisone is generally started first before moving to other therapies. Vamorolone potentially changes that in the future with a more favorable side effect profile and long term effect, but no changes have been made in practice.

5. Cole Sloan re-made a motion to include at least one corticosteroid for inclusion on the PDL. Bryan Larson seconded the motion. All in favor. Motion passed.
6. Cole Sloan asked about ASO and gene therapy utilization. Monet Luloh said the DRRC has looked back for 3 years and not found any Medicaid's ASO utilization. Russell Butterfield mentioned that the clinic uses all the exon skipper in appropriate patients but not many patients are Medicaid patients. Bryan Larson mentioned a historically PDL class for Spinal Muscular Dystrophy with the understanding that not all agents are equal in terms of safety and efficacy. These drugs are primarily managed by prior authorization but having a PDL class allows opportunities to accept rebate offers from manufacturers if any.
7. Bryan Larson made a motion to include DMD agents to be included on the PDL despite the fact that they are not equal in safety and efficacy. Rocky Parker seconded the motion. All in favor. Motion carried.
8. Yoon Kim-Butterfield mentioned that the UHCD resources are posted on the Utah Medicaid website.

5. **Public Meeting Adjourned:** Bryan Larson motioned to close the meeting. Unanimous Approval, meeting adjourned.

6. **Next meeting is scheduled for** Thursday, February 20, 2025.
a. Topic: EGFR Inhibitors.

7. **Meeting Chat Transcript:**

Pharmacy & Therapeutics Committee

Meeting Minutes

00:44:07.963,00:44:10.963

Andrea Rico (DHHS):

<https://medicaid.utah.gov/pharmacy/resource-library/> Ultra High Cost Drug Folder

00:44:11.762,00:44:14.762

Bryan Larson (DHHS):

<https://medicaid.utah.gov/pharmacy/resource-library/>

00:44:44.951,00:44:47.951

Bryan Larson (DHHS):

<https://medicaid.utah.gov/pharmacy/prior-authorization>

00:45:13.444,00:45:16.444

Robin Wells, BSN: Thank you!

Audio recording of all P&T meetings are available online at:

https://www.youtube.com/@dmhf_webdohdhhs2

PENDING